Utilization of Immunosuppressant Drug In Renal Transplant Recipients

Abstract

Background: Immunosuppressant drug prescribed to renal transplant recipients play a vital role in the graft and patient survival after transplant. newlineAim: Identification of trends of prescription pattern, superior drug regimen, effect of immunosuppressant drug on infection and New onset diabetes (NODAT). newlineMaterials and Methods: Retrospective and prospective study were conducted at Muljibhai Patel Urological Hospital, Nadiad. In a retrospective study, patients who underwent renal transplantation between July 2004 and June 2011 were enrolled and followed up till their last followed up visit on or before June 2012. Data including immunosuppressant drug prescription information, rejection episode, CNI toxicity, information for Infection and NODAT were collected. newlineIn prospective study, patients who underwent kidney transplantation between January 2013 and August 2013 were enrolled after prior permission from IRB of Institute. Relevant Data were collected and analyzed by SPSS software using chi square test and T test. newlineConclusion: We conclude that use of ATG, Tacrolimus, and MMF has increased between year 2004 and 2011 in renal transplant recipients. PTM is the most commonly used regimen and associated with better patient survival. Almost one-third patient develop NODAT which is more common in patients with elderly, higher HLA mismatch and receiving PTA regimen. Infections following renal transplant occur in almost more than two third of recipients. Use of ATG and increasing age is a risk factor for infection following renal transplant. newline